The companies said both boards of directors approved the "definitive agreement" which values Bard shares at $317.00 each.
BD, based in Franklin Lakes, New Jersey, said it expects the acquisition of Bard, which is based in the same state and specializes on vascular, urology and oncology products, to boost non-U.S.
growth options and to raise per-share earnings in fiscal year 2019.
Reuters is the news and media division of Thomson Reuters.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms.